Diepalrestat choline - BioNevia/NeuroMax

Drug Profile

Diepalrestat choline - BioNevia/NeuroMax

Alternative Names: BNV-222; Choline cocrystal of epalrestat - Bionevia Pharmaceuticals; Choline diepalrestat; NM-IA-001

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bionevia Pharmaceuticals
  • Developer BioNevia Pharmaceuticals; NeuroMax
  • Class Small molecules; Thiazolidines
  • Mechanism of Action Aldehyde reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Diabetic neuropathies

Most Recent Events

  • 05 Apr 2017 Chemical structure information added
  • 20 Mar 2017 Phase-II/III development is ongoing in Russia
  • 16 May 2016 BioNevia and NeuroMax completes enrolment in a phase II/III trial for Diabetic Neuropathy in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top